Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity

Toxicology Letters

Volumn 214, Issue 2, 2012, Pages 175-181

  Kim, Jae Ah ^a   Han, Eunyoung ^b   Eun, Chae Jung ^a   Tak, Yu Kyung ^a   Song, Joon Myong ^a  

^a Seoul National University   (South Korea)

^b National Forensic Service   (South Korea)

Author keywords

Apoptosis; Cytosolic calcium; Hepatotoxicity; High content screening; Mitochondria dysfunction; Real time monitoring

Indexed keywords

CALCIUM; CASPASE 3; CASPASE 8; DEXAMETHASONE; LACTATE DEHYDROGENASE; NEFAZODONE; PIROXICAM; TOLCAPONE; TROGLITAZONE;

APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CELL DEATH; CELL FUNCTION; CELL STRAIN HEPG2; CELL VIABILITY; CONTROLLED STUDY; HIGH CONTENT SCREENING; IN VITRO STUDY; LIVER TOXICITY; MITOCHONDRIAL MEMBRANE; MITOCHONDRIAL PERMEABILITY; PRIORITY JOURNAL; SCREENING;

APOPTOSIS; BENZOPHENONES; CALCIUM; CASPASE 3; CHROMANS; DRUG-INDUCED LIVER INJURY; HEP G2 CELLS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMIDAZOLES; LIVER; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA, LIVER; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; NITROPHENOLS; THIAZOLIDINEDIONES; TRIAZOLES;

ANIMALIA;

EID: 84866479079     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2012.08.027     Document Type: Article

References (21)

1. Berridge M.J., Bootman M.D., Roderick H.L. Calcium signalling: dynamics, homeostasis and remodelling. Nature Reviews Molecular Cell Biology 2003, 4:517-529.
2. Bova M.P., Tam D., McMahon G., Mattson M.N. Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicology Letters 2005, 155:41-50.
3. Chakraborti T., Das S., Mondal M., Roychoudhury S., Chakraborti S. Oxidant, mitochondria and calcium: an overview. Cellular Signalling 1999, 11:77-85.
4. Dong Z., Saikumar P., Weinberg J.M., Venkatachalam M.A. Calcium in cell injury and death. Annual Review of Pathology: Mechanisms of Disease 2006, 1:405-434.
5. Dykens J.A., Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discovery Today 2007, 12:777-785.
6. Dykens J.A., Jamieson J.D., Marroquin L.D., Nadanaciva S., Xu J.J., Dunn M.C., Smith A.R., Will Y. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicological Sciences 2008, 103:335-345.
7. Haasio K., Sopanen L., Vaalavirta L., Linden I.B., Heinonen E.H. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. Journal of Neural Transmission 2001, 108:79-91.
8. Hassio K., Koponen A., Penttila K.E., Nissinen E. Effects of entacapone and tolcapone on mitochondrial membrane potential. European Journal of Pharmacology 2002, 453:21-26.
9. Hynes J., Marroquin L.D., Ogurtsov V.I., Christiansen K.N., Stevens G.J., Papkovsky D.B., Will Y. Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes. Toxicological Sciences 2006, 92:186-200.
10. Jurima-Romet M., Crawford K., Huang H.S. Comparative cytotoxicity of non-steroidal anti-inflammatory drugs in primary cultures of rat hepatocytes. Toxicology in Vitro 1994, 8:55-66.
11. Masubuchi Y., Kano S., Horie T. Mitochondrial permeability transition as a potential determinant of hepatotoxicity of antidiabetic thiazolidinediones. Toxicology Letters 2006, 222:233-239.
12. Michelini E., Cevenini L., Mezzanotte L., Ablamsky D., Southworth T., Branchini B., Roda A. Spectral-resolved gene technology for multiplexed bioluminescence and high-content screening. Analytical Chemistry 2008, 80:260-267.
13. Nadanaciva S., Bernal A., Aggeler R., Capaldi R., Will Y. Target identification of drug induced mitochondrial toxicity using immunocapture based OXPHOS activity assays. Toxicology in Vitro 2007, 21:902-911.
14. Naoghare P.K., Ki H.A., Paek S.M., Tak Y.K., Suh Y.G., Kim S.G., Song J.M. Simultaneous quantitative monitoring of drug-induced caspase cascade pathways in carcinoma cells. Integrative Biology 2010, 2:46-57.
15. 2+ homeostasis. Neuroscience Research 2000, 37:227-236.
16. Pessayre D., Mansouri A., Berson A., Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handbook of Experimental Pharmacology 2010, 196:311-365.
17. Scheffler I.E. Mitochondria. 1999, Wiley-Liss Inc., New York, 367 pp.
18. Schembri L., Zanese M., Depierre-Plinet G., Petit M., Elkaoukabi-Chaibi A., Tauzin L., Florean C., Lartigue L., Medina C., Rey C., Belloc F., Reiffers J., Ichas F., De Giorgi F. Recombinant differential anchorage probes that tower over the spatial dimension of intracellular signals for high content screening and analysis. Analytical Chemistry 2009, 81:9590-9598.
19. Song M., Kim Y.J., Ryu J.C. Induction of ROS, p38 MAP kinase and apoptosis via pulmonary toxic drugs. BioChip Journal 2009, 3:306-315.
20. Wlodkowic D., Khoshmanesh K., Sharpe J.C., Darzynkiewicz Z., Cooper J.M. Apoptosis goes on a chip: advances in the microfluidic analysis of programmed cell death. Analytical Chemistry 2011, 83:6349-6446.
21. +-ATPase to hypertrophy and its marker genes in cardiac myocytes. Journal of Biological Chemistry 1999, 274:19323-19328.